The White House announced pricing agreements with nine major drugmakers—including Amgen, Bristol Myers Squibb, Gilead, Merck and Novartis—aimed at lowering Medicaid prices toward levels paid by peer nations. Administration officials described the set as the biggest tranche to date and said the deals will affect an estimated 30%–40% of Medicaid drug spend in certain areas. The agreements mirror prior most‑favored‑nation style negotiations and arrived as part of an end‑of‑year push to deliver on drug‑pricing commitments. Companies participating pledged price concessions and, in some cases, adjustments to Medicaid pricing frameworks. The move signals continued executive‑branch efforts to reshape drug pricing outside of traditional Congressional legislation, and it will shape manufacturers’ commercial strategies and negotiations with payers in the U.S. market.